Sequence of a fusogenic herpes simplex virus, RH2, for oncolytic virotherapy

Journal of General Virology

Volumn 94, Issue PART4, 2013, Pages 726-737

  Takahashi, Gen ^a   Meshii, Noritoshi ^a   Hamada, Masakazu ^a   Iwai, Soichi ^a   Yura, Yoshiaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; GINSENOSIDE RH 2; VIRUS DNA;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; DNA SEQUENCE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PYROSEQUENCING; VIRUS MUTANT;

EID: 84875639397     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.044834-0     Document Type: Article

References (62)

1. Albert, I., Mavrich, T. N., Tomsho, L. P., Qi, J., Zanton, S. J., Schuster, S. C. & Pugh, B. F. (2007). Translational and rotational settings of H2A.Z nucleosomes across the Saccharomyces cerevisiae genome. Nature 446, 572-576.
2. Andreansky, S., Soroceanu, L., Flotte, E. R., Chou, J., Markert, J. M., Gillespie, G. Y., Roizman, B. & Whitley, R. J. (1997). Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57, 1502-1509.
3. Atanasiu, D., Whitbeck, J. C., de Leon, M. P., Lou, H., Hannah, B. P., Cohen, G. H. & Eisenberg, R. J. (2010). Bimolecular complementation defines functional regions of herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol 84, 3825-3834.
4. Baines, J. D., Ward, P. L., Campadelli-Fiume, G. & Roizman, B. (1991). The UL20 gene of herpes simplex virus 1 encodes a function necessary for viral egress. J Virol 65, 6414-6424.
5. Bzik, D. J., Fox, B. A., DeLuca, N. A. & Person, S. (1984). Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: mutations affecting rate of virus entry and cell fusion. Virology 137, 185-190.
6. Cai, W. H., Gu, B. & Person, S. (1988). Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. J Virol 62, 2596-2604.
7. Carfí, A., Willis, S. H., Whitbeck, J. C., Krummenacher, C., Cohen, G. H., Eisenberg, R. J. & Wiley, D. C. (2001). Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell 8, 169-179.
8. Chouljenko, V. N., Iyer, A. V., Chowdhury, S., Kim, J. & Kousoulas, K. G. (2010). The herpes simplex virus type 1 UL20 protein and the amino terminus of glycoprotein K (gK) physically interact with gB. J Virol 84, 8596-8606.
9. Chowdary, T. K., Cairns, T. M., Atanasiu, D., Cohen, G. H., Eisenberg, R. J. & Heldwein, E. E. (2010). Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol 17, 882-888.
10. Crump, C. M., Bruun, B., Bell, S., Pomeranz, L. E., Minson, T. & Browne, H. M. (2004). Alphaherpesvirus glycoprotein M causes the relocalization of plasma membrane proteins. J Gen Virol 85, 3517-3527.
11. Diakidi-Kosta, A., Michailidou, G., Kontogounis, G., Sivropoulou, A. & Arsenakis, M. (2003). A single amino acid substitution in the cytoplasmic tail of the glycoprotein B of herpes simplex virus 1 affects both syncytium formation and binding to intracellular heparan sulfate. Virus Res 93, 99-108.
12. Dolter, K. E., Ramaswamy, R. & Holland, T. C. (1994). Syncytial mutations in the herpes simplex virus type 1 gK (UL53) gene occur in two distinct domains. J Virol 68, 8277-8281.
13. Forrester, A., Farrell, H., Wilkinson, G., Kaye, J., Davis-Poynter, N. & Minson, T. (1992). Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. J Virol 66, 341-348.
14. Foster, T. P., Melancon, J. M. & Kousoulas, K. G. (2001). An a-helical domain within the carboxyl terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) is associated with cell fusion and resistance to heparin inhibition of cell fusion. Virology 287, 18-29.
15. Foster, T. P., Alvarez, X. & Kousoulas, K. G. (2003). Plasma membrane topology of syncytial domains of herpes simplex virus type 1 glycoprotein K (gK): the UL20 protein enables cell surface localization of gK but not gK-mediated cell-to-cell fusion. J Virol 77, 499-510.
16. Fu, X. & Zhang, X. (2002). Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 62, 2306-2312.
17. Fu, X., Tao, L., Jin, A., Vile, R., Brenner, M. K. & Zhang, X. (2003). Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 7, 748-754.
18. Fujimoto, Y., Mizuno, T., Sugiura, S., Goshima, F., Kohno, S., Nakashima, T. & Nishiyama, Y. (2006). Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 126, 1115-1117.
19. Gage, P. J., Levine, M. & Glorioso, J. C. (1993). Syncytium-inducing mutations localize to two discrete regions within the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B. J Virol 67, 2191-2201.
20. Geraghty, R. J., Krummenacher, C., Cohen, G. H., Eisenberg, R. J. & Spear, P. G. (1998). Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 280, 1618-1620.
21. Harrington, K. J., Hingorani, M., Tanay, M. A., Hickey, J., Bhide, S. A., Clarke, P. M., Renouf, L. C., Thway, K., Sibtain, A. & other authors (2010). Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 16, 4005-4015.
22. Hiller, N. L., Janto, B., Hogg, J. S., Boissy, R., Yu, S., Powell, E., Keefe, R., Ehrlich, N. E., Shen, K. & other authors (2007). Comparative genomic analyses of seventeen Streptococcus pneumoniae strains: insights into the pneumococcal supragenome. J Bacteriol 189, 8186-8195.
23. Hutchinson, L., Goldsmith, K., Snoddy, D., Ghosh, H., Graham, F. L. & Johnson, D. C. (1992). Identification and characterization of a novel herpes simplex virus glycoprotein, gK, involved in cell fusion. J Virol 66, 5603-5609.
24. Hutchison, C. A., III (2007). DNA sequencing: bench to bedside and beyond. Nucleic Acids Res 35, 6227-6237.
25. Israyelyan, A., Chouljenko, V. N., Baghian, A., David, A. T., Kearney, M. T. & Kousoulas, K. G. (2008). Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virol J 5, 68.
26. Kemeny, N., Brown, K., Covey, A., Kim, T., Bhargava, A., Brody, L., Guilfoyle, B., Haag, N. P., Karrasch, M. & other authors (2006). Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17, 1214-1224.
27. Klupp, B. G., Granzow, H., Karger, A. & Mettenleiter, T. C. (2005). Identification, subviral localization, and functional characterization of the pseudorabies virus UL17 protein. J Virol 79, 13442-13453.
28. Klyachkin, Y. M., Stoops, K. D. & Geraghty, R. J. (2006). Herpes simplex virus type 1 glycoprotein L mutants that fail to promote trafficking of glycoprotein H and fail to function in fusion can induce binding of glycoprotein L-dependent anti-glycoprotein H antibodies. J Gen Virol 87, 759-767.
29. Ko, D. H., Cunningham, A. L. & Diefenbach, R. J. (2010). The major determinant for addition of tegument protein pUL48 (VP16) to capsids in herpes simplex virus type 1 is the presence of the major tegument protein pUL36 (VP1/2). J Virol 84, 1397-1405.
30. Ligas, M. W. & Johnson, D. C. (1988). A herpes simplex virus mutant in which glycoprotein D sequences are replaced by b-galactosidase sequences binds to but is unable to penetrate into cells. J Virol 62, 1486-1494.
31. Liu, B. L., Robinson, M., Han, Z. Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M. & other authors (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10, 292-303.
32. MacKie, R. M., Stewart, B. & Brown, S. M. (2001). Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357, 525-526.
33. Manoj, S., Jogger, C. R., Myscofski, D., Yoon, M. & Spear, P. G. (2004). Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proc Natl Acad Sci USA 101, 12414-12421.
34. Margulies, M., Egholm, M., Altman, W. E., Attiya, S., Bader, J. S., Bemben, L. A., Berka, J., Braverman, M. S., Chen, Y. J. & other authors (2005). Genome sequencing in microfabricated high-density picolitre reactors. Nature 437, 376-380.
35. McGeoch, D. J., Dalrymple, M. A., Davison, A. J., Dolan, A., Frame, M. C., McNab, D., Perry, L. J., Scott, J. E. & Taylor, P. (1988). The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 69, 1531-1574.
36. McKnight, J. L., Kristie, T. M. & Roizman, B. (1987). Binding of the virion protein mediating alpha gene induction in herpes simplex virus 1-infected cells to its cis site requires cellular proteins. Proc Natl Acad Sci U S A 84, 7061-7065.
37. Melancon, J. M., Foster, T. P. & Kousoulas, K. G. (2004). Genetic analysis of the herpes simplex virus type 1 UL20 protein domains involved in cytoplasmic virion envelopment and virus-induced cell fusion. J Virol 78, 7329-7343.
38. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D. & Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938-943.
39. Montgomery, R. I., Warner, M. S., Lum, B. J. & Spear, P. G. (1996). Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427-436.
40. Nakamori, M., Fu, X., Meng, F., Jin, A., Tao, L., Bast, R. C., Jr & Zhang, X. (2003). Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 9, 2727-2733.
41. Nakao, A., Kimata, H., Imai, T., Kikumori, T., Teshigahara, O., Nagasaka, T., Goshima, F. & Nishiyama, Y. (2004). Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 15, 988-989.
42. Nakao, A., Kasuya, H., Sahin, T. T., Nomura, N., Kanzaki, A., Misawa, M., Shirota, T., Yamada, S., Fujii, T. & other authors (2011). A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther 18, 167-175.
43. Newcomb, W. W. & Brown, J. C. (2010). Structure and capsid association of the herpesvirus large tegument protein UL36. J Virol 84, 9408-9414.
44. Ogawa, F., Takaoka, H., Iwai, S., Aota, K. & Yura, Y. (2008). Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Anticancer Res 28 (6A), 3637-3645.
45. Peng, T., Ponce-de-Leon, M., Jiang, H., Dubin, G., Lubinski, J. M., Eisenberg, R. J. & Cohen, G. H. (1998). The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J Virol 72, 65-72.
46. Roop, C., Hutchinson, L. & Johnson, D. C. (1993). A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H. J Virol 67, 2285-2297.
47. Rowan, K. (2010). Oncolytic viruses move forward in clinical trials. J Natl Cancer Inst 102, 590-595.
48. Shukla, D., Liu, J., Blaiklock, P., Shworak, N. W., Bai, X., Esko, J. D., Cohen, G. H., Eisenberg, R. J., Rosenberg, R. D. & Spear, P. G. (1999). A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99, 13-22.
49. Shukla, D., Dal Canto, M. C., Rowe, C. L. & Spear, P. G. (2000). Striking similarity of murine nectin-1a to human nectin-1a (HveC) in sequence and activity as a glycoprotein D receptor for alphaherpes virus entry. J Virol 74, 11773-11781.
50. Simpson, G. R., Han, Z., Liu, B., Wang, Y., Campbell, G. & Coffin, R. S. (2006). Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 66, 4835-4842.
51. Spatz, S. J. & Rue, C. A. (2008). Sequence determination of a mildly virulent strain (CU-2) of Gallid herpesvirus type 2 using 454 pyrosequencing. Virus Genes 36, 479-489.
52. Swaminathan, K., Varala, K. & Hudson, M. E. (2007). Global repeat discovery and estimation of genomic copy number in a large, complex genome using a high-throughput 454 sequence survey. BMC Genomics 8, 132.
53. Szpara, M. L., Parsons, L. & Enquist, L. W. (2010). Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations. J Virol 84, 5303-5313.
54. Takakuwa, H., Goshima, F., Nozawa, N., Yoshikawa, T., Kimata, H., Nakao, A., Nawa, A., Kurata, T., Sata, T. & Nishiyama, Y. (2003). Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 148, 813-825.
55. Takaoka, H., Takahashi, G., Ogawa, F., Imai, T., Iwai, S. & Yura, Y. (2011). A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma. Virol J 8, 294.
56. Tiwari, V., Clement, C., Scanlan, P. M., Kowlessur, D., Yue, B. Y. J. & Shukla, D. (2005). A role for herpesvirus entry mediator as the receptor for herpes simplex virus 1 entry into primary human trabecular meshwork cells. J Virol 79, 13173-13179.
57. Torres, T. T., Metta, M., Ottenwalder, B. & Schlotterer, C. (2008). Gene expression profiling by massively parallel sequencing. Genome Res 18, 172-177.
58. Ushijima, Y., Luo, C., Goshima, F., Yamauchi, Y., Kimura, H. & Nishiyama, Y. (2007). Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes Infect 9, 142-149.
59. Wagner, M. J. & Smiley, J. R. (2011). Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling. J Virol 85, 2803-2812.
60. Walev, I., Lingen, M., Lazzaro, M., Weise, K. & Falke, D. (1994). Cyclosporin A resistance of herpes simplex virus-induced "fusion from within" as a phenotypical marker of mutations in the Syn 3 locus of the glycoprotein B gene. Virus Genes 8, 83-86.
61. Wheeler, C. E. (1958). The effect of temperature upon the production of herpes simplex virus in tissue culture. J Immunol 81, 98-106.
62. Zahariadis, G., Wagner, M. J., Doepker, R. C., Maciejko, J. M., Crider, C. M., Jerome, K. R. & Smiley, J. R. (2008). Cell-type-specific tyrosine phosphorylation of the herpes simplex virus tegument protein VP11/12 encoded by gene UL46. J Virol 82, 6098-6108.